Oncology News

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

BOSTON — Direct-acting antiviral therapy for hepatitis C virus-related hepatocellular carcinoma significantly improves overall survival, but only one in four patients receive therapy, even with insurance, according to a researcher.

BOSTON — Transarterial chemoembolization with vitamin K dosing improved anticancer outcomes of objective response and progression-free survival in patients with hepatocellular carcinoma, according to a researcher at The Liver Meeting.

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

Postdiagnosis antidepressant use reduced mortality risk among patients with hepatocellular carcinoma, according to data published in JAMA Network Open.

Rates of hepatocellular carcinoma caused by alcohol-related disease and nonalcoholic fatty liver disease are on the rise, especially among Hispanic individuals, according to research in Clinical Gastroenterology and Hepatology.

Type 2 diabetes was an independent predictor of hepatic decompensation and development of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease, according to data.

Proteins and genetic material secreted by fatty liver cells stimulate the spread of colorectal cancer to the liver, study results published in Cell Metabolism showed.

Research demonstrated that hepatocellular carcinoma surveillance is cost-effective at a lower incidence threshold of 0.7% in virologically cured patients with hepatitis C virus, underscoring the need to update clinical guidelines.